| **Study Reference** | **Participant Characteristics** | **Intervention; Duration** | **Incident Fracture VertebralRisk in Treatment Group; Risk in Control Group**  **(RR [95% CI])** | **Incident Fracture NonvertebralRisk in Treatment Group; Risk in Control Group**  **(RR [95% CI])** | **HipRisk in Treatment Group; Risk in Control Group**  **(RR [95% CI])** | **Other Incident FracturesRisk in Treatment Group; Risk in Control Group**  **(RR [95% CI])** | **Quality Rating** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| McClung et al, 2001223 | Women 70 years and older;, mean femoral neck T-score -3.7 | Risedronate 5 mg/day; 2 years treatment (mean follow-up 2.3 years) | NR | NR | 137/6197; 95/3134  [0.73 (0.56 to 0.94)]  Subgroup aged 70-79 without prevalent vertebral fractureb  14/1773; 12/875  [0.58 (0.27 to 1.24)] | NR | Fair |
| Mortensen et al, 1998224 | Women 6-60 months postmenopausal; mean age 51.5 years; mean T-score -1.1; no prior osteoporotic fracture | Risedronate 5 mg/day; 2 years treatment (follow-up 3 years) | 1/37; 0/36  [2.92 (CI, 0.12-69.43)] a | 0/37; 3/36  [0.14 (0.01-2.60)]a | 0/37; 0/36  RR not estimablea | NR | Fair |
| Valimaki et al, 2007225 | Women ≥5 years postmenopausal; osteoporosis risk factors or low hip BMD; mean age 65.9 years; mean femoral neck T-score -1.2; unknown prior fracture | Risedronate 5 mg/day; 2 years | 0/114; 0/56  RR not estimablea | 2/114; 2/56  0.49 (0.07-3.40) a | NR | NR | Fair |
| cFogelman et al, 2000226 | Postmenopausal women less than age 80 years, with mean lumbar T-score of -2.0 or less; mean age 65 years; 31 % with vertebral fractures | Risedronate 5 mg/day; 2 years | 8/112;17/125  [0.53 (0.24 to 1.17)] a | 7/112;13/125  [0.68 (0.30 to 1.58)] a | NR | NR | Fair |

a Fractures were not primary or secondary efficacy measures in these studies, and studies were not powered based on fracture outcomes.

b Results from a post-hoc analysis of women aged 70 to 79 without prevalent vertebral fracture at baseline. The RR in women aged 70-79 with prevalent vertebral fracture at baseline was 0.4 (95% CI, 0.2 to 0.8).

c Excluded from previous review because >=20% of study had prior or prevalent fracture; however, this study was considered in the prior review’s sensitivity analysis.

**Abbreviations:** BMD=bone mineral density; CI=confidence interval; mg=milligram; NR=not reported; RR=risk ratio.